| INTRODUCTION
In recent years, pancreatic cancer is accounted as one of the most incurable malignancies in which majority of the victims are recognized after the development of metastasis. Recent developments have been made in understanding the molecular features of pancreatic cancer as well as cancer prediction, staging, and treatment methods. The treatment of pancreatic cancer leads to increased mortality due to the tendency of early spread of cancer as well as it is highly resistant against chemotherapy and radiation.
1 Limitations in diagnosing this disastrous disease at early stage results in unfavorable outcomes.
Reports showed that gemcitabine was introduced as first-line agent which provides positive clinical responses including weight gain and lowered pain, 2 but still the survival rate remains small of about 1%-5%
of 5 years and 4-6 months of median survival period. [3] [4] [5] [6] [7] Circulating tumor cells (CTCs) are atypical cells which are rare as one cell among 10 9 hematological cells that can be found in cancer patients' blood and hence the separation remains an obstacle. [8] [9] [10] [11] In recent decades, it has been observed that gaining knowledge in tumor biology has improved but significant improvement in treating or curing pancreatic cancers has not been achieved. Considerable challenges prevail in acquiring tissues from patients affected with pancreatic cancer for histological identification. Obtaining pre-and post-treatment tumor biopsies to detect pharmacodynamic features during medical trials of creative treatment methods are even tougher. At present, the unsatisfactory results are obtained from surgical treatments in pancreatic cancer because the post-operative patients end up with metastasis soon after the surgery leading to death. discussed and hence, we herein report the detection and management of circulating tumor cells in pancreatic cancer.
| MATERIALS AND METHODS

| Methods
About 120 samples of blood and bone marrow samples were collected from pancreatic cancer patients and 57 controls during February 2013 and October 2014. The blood samples were acquired from the patients during their hospital visit not exceeded more than 4 weeks before surgical operation. The bone marrow was obtained from the patient when they were subjected to anesthesia just before the surgery. Pancreatic cancer patients (63 men and 57 women) with an average age of 61 diagnosed from their tissue sections were divided based on Union Internationale Contre le Cancer classification of TNM as shown in Table 1 . 
| Presurgical procedures and its therapy
To find out the stage of cancer and metastases stage of cancer patients, computed tomographic (CT) scans with enhanced contrast were conducted. About 78% of patients were subjected to undergo laparoscopy and biopsy tests. Most of the resections carried out were of limited pancreatico-duodenectomy of about 78% while three patients had complete pancreatico-duodenectomy and a distal pancreatic resection was done in another two patients. Phase IVa patients of about 64% (28/44) were undergone abdominal exploration and soothing operation methods whereas IVb patients with metastases (liver) (17/34) were detected by CT scan/laparoscopy and metastases (peritoneal)
were identified with laparoscopy/PWC (14/34), or four patients with both liver and peritoneal metastases (4/34) were also found.
| Sampling and processing of blood and bone marrow
Blood samples (10-15 mL) from the outpatients were collected according to the conditions of University Hospital before surgery and bone marrow samples were taken from 48 pancreatic cancer patients. Both blood and bone marrow samples were stored in EDTA and utilized within 5 hours.
The methods of separating the cancer cell possessing mono-nuclear cell community and immunocytochemical assays were fixed using sus- was performed with related controls on healthy individual's cytospins and tissue section from two different pancreatic cancer patients were used as positive controls. The slides were marked with codes and analyzed blindly. The cells stained positive for AE1/AE3 antibody were counted as tumor cells (Figure 1 ).
| Preliminary studies
Six of monoclonal antibodies which specifically recognizing epithelial cell specific antigens were examined for specificity to identify the cancer cells in blood/bone marrow of the cancer patients. The antibodies were pointed at cytokeratin CK which includes AE1/AE3, CK7, CK19 and CK20. Glycoproteins found at the surface and thee epithelial cell cytoplasm were recognized by BER-EP4 antibody and anti-CA19-9 was used to detect a cancer biomarker. The control samples showed negative.
The investigation of blood from control group and cancer group in- anti-CK20 and anti-CA19-9, respectively. Only AE1/AE3-antibody was found to be more specific among all the antibodies tested. AE1 antibody identifies acidic keratins whereas AE3 recognizes basic keratins.
| Statistical analysis
Two-tailed chi square test was used to calculate the variations in the occurrence of isolated cancer cells between two patient groups using 
| RESULTS
| Detection of tumor cells in blood cells of pancreatic cancer patients
The occurrence of cells positive to AE1/AE3 antibodies found in the blood of 120 patients blood with pancreatic ductal adenocarcinoma was 29%. There was considerable increase in the stages of tumor.
About 11% (4/36) of circulating tumor cells were present in resectable cancer patients, whereas in non-resectable cancer patients 37%
(31/84) were found. There was no any significant changes found be- 
| Similarity between results from blood and bone marrow samples
The blood and bone marrow samples were obtained from the patients 
| Analysis of survival rate
About 26 survived out of 116 patients during the entire study period on the survival rate when the whole group was compared or the subgroup as listed in Table 2 .
Analysis of variables of the patient's survival rate revealed that different stages of tumor was alone found to predict the survival rate.
Eventhough there was some relationship found between isolated Tables 3 and 4 .
The different stages of tumor are forecasters of survival of patients.
The detection of tumor cells was not correlated with the prediction of survival from both the blood samples (n=120) and bone marrow samples (n=48) or from the overall isolated tumor cells from blood and bone marrow samples. Also these tumor cells were not involved in survival rate prediction when they considered at individual tumor stage.
The survival rate was calculated by using multivariate cox model to check whether the tumor cells isolated from blood and bone marrows has any significance in the survival of the patients. Out of the 116 patients group who were followed up, the tumor stage itself (P=.0001), resectable (P=.002) and dispersed cancer against localized in unresectable cancer (P=.01) had considerable relationship with survival.
The AE1/AE3 positive cells in blood samples did not show any significance in the survival of the patients as shown in Table 3 . Analysis about association between tumor cells isolated and different stages of tumor in a subgroup revealed a relationship between the tumor cells and the survival. There was no relationship found between the tumor cells and survival in patients where both blood and bone marrow samples were collected (n=48). The tumor cells isolated from both the blood and bone marrow samples was not related to survival in all of the analysis as shown in Table 4 .
| DISCUSSION
The circulating tumor cells can help to find the molecules that are in- (14) 16 (12) Stage IVb (35) 11 (8) 10 (8) a Two patients were not followed up due to lost in contact and two patients died during the study.
T A B L E when compared with other studies reporting circulating tumor cells by using multiple antibodies with varying specificity. 
